The decrease came as improved performance by its biopharma services operations was more than offset by declines in clinical and discovery services revenues.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.
The probes are for use in Cancer Genetics' FISH-based HPV-Associated Cancer Test, which measures genomic changes to help triage cervical cancer patients.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
